Greece Hospital Anti-infectives Market Size, Share, Growth, Trends, and Global Industry Analysis: Size, Share, Growth, Trends, and Industry Analysis By Drug Type (Antibiotics, Antivirals, Antifungal, Others), Disease condition (Respiratory Infection, Pneumonia, HIV, Tuberculosis, Others), By Route of Administration (Oral, Topical, Parentals and Others), By Distribution channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Country Forecast 2020-2031

Greece Hospital Anti-infectives Market size was valued at US$ 410 million in 2024 and is projected to reach US$ 540 million by 2031, growing at a 4.0% CAGR from 2025–2031. The market is expanding on a narrowing edge of clinical need and medical progress. Widespread antimicrobial resistance and increasing hospital-acquired infection create mounting demand for targeted, broad-spectrum anti-infective treatment. Increased use of antibiotics and an aging population in Greece have made the treatment of infectious disease a matter of policy priority, leading to increased focus on antimicrobial stewardship and restriction on prescription. Though the public hospitals are the biggest prescribers, private clinics and outpatient care facilities are increasingly looking towards next-generation antivirals and antifungals.

Furthermore, Southeast Europe's local drug industry is also expanding its scope not just to generics production but also to contract production for international companies wishing to enter Southeast European markets.

Facts & Figures

• Greece remains among the European Union's biggest antibiotic users, creating consistent market demand for anti-infective therapy in outpatients as well as inpatients.
• Over 60% of hospitalized Greek patients receive more than one anti-infective, with the most prescribed classes of drugs being cephalosporins and penicillins
• Generic anti-infectives acquired through the central procurement system are used increasingly by public hospitals, whereas private clinics increasingly prefer new-generation, combination-based products.
• National schemes for e-prescription and monitoring are also being improved to aid antimicrobial stewardship programs as well as appropriate prescribing, in accordance with EU AMR containment measures.

Key Developments

• In July 2024, Daiichi Sankyo consolidate its European oncology footprint through the launch of a new affiliate in Athens, Greece, in line with its vision for cancer treatment innovation within the region.
• In December 2023, Greece was part of a strategic distribution agreement between Shionogi B.V. and Sobi for Fetcroja® (cefiderocol), enhancing access to next-generation antibiotics for multidrug-resistant infections.
• In November 2023, Omnix Medical received FDA approval in November 2023 to initiate Phase II trials of OMN6, a next-generation antimicrobial peptide, with possible future use for the Greek anti-infectives market as resistance challenges mount. These developments constitute a regional trend towards next-generation anti-infectives, border-crossing collaborations, and greater access to new therapeutic agents in Greece's infectious disease treatment pipeline.

Greece Hospital Anti Infectives Market Segmentation

Based on the drug type

• Antibiotics
• Antivirals
• Antifungal
• Others

Antibiotics remain the cornerstone of Greece's anti-infectives market owing to traditional prescribing behavior and the ubiquity of bacterial infections in the nation. Despite increasing antimicrobial resistance (AMR), broad-spectrum antibiotics like cephalosporins and penicillins remain first-line drugs in public and private practices. Intravenous antibiotics are largely reliant on in hospitals, particularly surgical and intensive care units, for infection and prevention of infections. Where stewardship activities are being conducted, demand for antibiotics still exists based on the rate of respiratory and urinary tract infections among older patients. The generics sector in Greece also contributes by making low-cost antibiotic preparations available, maintaining supply steady even under cost-cutting procurement practices.

Based on the disease condition

• Respiratory Infections
• Pneumonia
• HIV
• Tuberculosis
• Others

Respiratory infections are a significant proportion of anti-infective consumption in Greece, owing to seasonable epidemic influenza, chronic obstructive pulmonary disease exacerbation, and widespread smoking-related complications. The high proportion of elderly inhabitants of the country is most susceptible to pneumonias caused by bacteria and viral respiratory tract infection and therefore is responsible for steady demand for antibiotics and antiviral agents. Hospitalization for respiratory disease commonly involves multi-drug therapies that commence via empirical use of antibiotics. Although overuse is a problem, doctors increasingly utilize testing to select cause pathogens and thus provide more targeted treatments. Throughout the COVID-19 pandemic, redefining patient treatment policy, awareness for appropriate treatment of respiratory infections has been greater, to the benefit of institutional and outpatient utilization of anti-infectives.

Based on the route of administration

• Oral
• Topical
• Parentals
• Others

Parenteral anti-infectives are sweeping the Greek market, particularly in hospital therapy where drug administration should be instant and controlled. Intravenous (IV) administration is favored for severe bacterial infections, sepsis, and surgical prophylaxis. Most Greek hospitals adopt EU-compatible treatment regimens that include injectable antibiotics in the initial phases of therapy. New parenteral antivirals and antifungals are also used more in oncology and transplant units to treat immunocompromised patients. The high percentage of domestic contract manufacturers that can make sterile products also ensures availability and affordability of parenteral drugs. The applicability of this segment is also complemented by low outpatient follow-up in rural settings, and hospitals as central facilities for intensive care.

Based on the distribution channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Hospital pharmacies constitute the backbone of the anti-infectives chain of distribution in Greece. As a result of the extensive utilization of public sector health and national insurance programs, most severe infections are diagnosed and treated in hospitals. These pharmacies buy anti-infectives in bulk through cost-saving generic products offered by government-sponsored tenders. In addition to carrying essential antibiotics, hospital pharmacies increasingly carry newer-generation antivirals and antifungals, especially for intensive care, oncology, and transplant services. The introduction of electronic prescription and inventory systems has also enhanced tracking and reordering cycles. In the wake of increased emphasis on stewardship in hospitals, pharmacists are now more taking on more active roles in overseeing rational use of drugs and making them available and complying with changing national guidelines on treatment.